ORF, plasmid and mRNA for targeted degradation of intracellular protein, and use method and application of ORF, plasmid and mRNA

By using an open reading frame and lipid nanoparticle delivery system to achieve specific recognition and ubiquitination labeling of target proteins, this technology solves the problems of limited applicability of protein interference technology and high cost of PROTAC in existing technologies. It achieves efficient and safe target protein degradation and avoids off-target effects and genome integration risks.

CN118979049AActive Publication Date: 2024-11-19DALIAN UNIV OF TECH +1

Patent Information

Application Number
CN202411054589.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19
Estimated Expiration
2044-08-02

AI Technical Summary

Technical Problem

Existing DNA and RNA level protein interference technologies have limited applicability, require large dosages of small molecule drugs, lack universality, and are prone to off-target effects; PROTAC has high chemical synthesis costs, poor absorption, poor drug-like properties, and off-target toxicity; protein-targeted degradation technologies based on ubiquitination pathways still suffer from problems such as complex introduction of targeting modules and unfriendly modes of action.

Method used

An open reading frame is provided, consisting of a targeting module, a linking module, and a degradation module. The targeting module and the degradation module are connected by the linking module. The targeting module is a specifically bound polypeptide or protein, the linking module is a GSSS flexible peptide, and the degradation module is a part of the TRIM21 protein. It enters the cell through an mRNA and lipid nanoparticle delivery system to achieve specific recognition and ubiquitination labeling of the target protein, and degrades the target protein via the ubiquitin-proteasome pathway.

Benefits of technology

It achieves efficient and continuous degradation of target proteins, avoids off-target effects, is universally applicable, simple to operate, highly safe, and reliable in production. It can completely remove target proteins within ten minutes, avoiding the risks of genome integration and cell transformation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979049A_ABST
    Figure CN118979049A_ABST
Patent Text Reader

Abstract

The invention discloses ORF, plasmid and mRNA for targeted degradation of intracellular protein as well as a use method and application of the ORF, plasmid and mRNA, and belongs to the technical field of target protein degradation. The method provided by the invention can effectively and continuously degrade the target protein, and has high efficiency and expandability; the specific recognition function on a target protein is achieved through antigen-antibody specific hybridization reaction, the inevitable off-target effect of a CRISPR technology, a PROTACs technology, an RNAi technology and the like is avoided, and the method has universality, can be applied to any endogenous protein and can distinguish different variants of one protein; the introduction of the targeting module is simple and easy to operate, and the target protein does not need to be modified in advance; the mRNA medicine can be safely and efficiently delivered to cells and protected from being degraded, and does not need to enter cell nucleuses, so that the safety risk of genome integration and cell transformation can be avoided; the production is safe and reliable, and the production is realized through an enzymatic in vitro transcription (IVT) reaction without depending on a cell amplification process, so that the complex production problem related to cell culture is avoided.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of target protein degradation, and in particular to an ORF, a plasmid and an mRNA for targeted degradation of intracellular proteins, and a use method and application thereof. Background Art

[0002] As the main bearer of life activities, the expression and degradation of proteins are the basis for maintaining cell functions and supporting the physiological functions of the body, and are precisely regulated by the cell's own regulatory network. Abnormal expression and misfolding of proteins in the body often lead to abnormal accumulation of the protein in the cell, which in turn leads to the occurrence and development of related diseases. For example, the pathogenesis of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease, which have received increasing attention in recent years, as well as some malignant tumors, are closely related to the abnormal accumulation of proteins. It can be seen that strengthening and interfering with the expression and function of proteins is not only the main strategy for studying gene function in basic research, but also an effective means to prevent and treat related diseases caused by protein dysfunction.

[0003] At present, protein editing technologies mainly include the following types:

[0004] (1) Protein interference technology acting at the DNA and RNA levels

[0005] In recent years, with the emergence of gene editing technologies such as CRISPR / Cas9, this type of protein interference method that directly acts on the DNA level has been widely used due to its simple and convenient operation and strong applicability. Methods that act on the RNA level, such as RNAi technology, can reduce the expression of target proteins by affecting the stability of target protein mRNA or interfering with its translation process. They are also widely used to knock down or even completely knock out protein expression.

[0006] However, whether it is protein interference methods targeting DNA or RNA levels, the depletion of proteins in cells is indirect, which makes the protein knockdown effect strongly dependent on the intrinsic turnover rate of proteins inside the cell. This means that cells may have enough time to activate compensatory mechanisms to mask the phenotype, making it unclear whether the phenotype is a direct consequence of gene knockout. Faced with proteins of equal lifespan, such indirect protein interference methods targeting DNA and RNA are completely ineffective.

[0007] (2) Technology for conditional inactivation of proteins at the protein level

[0008] ① Small molecule inhibitors

[0009] Small molecule inhibitors are mainly based on the occupancy-driven drug action mode, which inhibits the activity and function of target enzymes or receptors by occupying or blocking their active sites, thereby exerting therapeutic effects. However, small molecule inhibitors have inherent limitations in practical applications:

[0010] 1) Large dosage: In the actual medication process, since small molecule drugs achieve target protein activity inhibition through a space-occupying-driven model, in order to achieve a better therapeutic effect (IC90), the protein target needs to be continuously exposed to a high concentration of drug environment for a long time, which makes the dosage of small molecule drugs larger.

[0011] 2) Poor selectivity and off-target effects: Small molecule drugs are not only difficult to achieve high specificity, but also have many potential binding targets. In addition, small molecule drugs need to maintain a high-concentration drug environment throughout the body, which is likely to produce "off-target effects" and make side effects uncontrollable.

[0012] 3) Non-universality of drug development: Mechanism-based drug discovery is the mainstream method for the development of small molecule new drugs. To design drugs for new targets, it is necessary to first have a comprehensive understanding of the active center of the target protein structure, design from scratch and screen out highly effective drugs on a large scale, which makes it difficult to form a unified universal method. In addition, small molecules need to bind to the active site of the target to work, which directly limits the drug targeting space.

[0013] Therefore, the existence of "undruggable" targets greatly limits the potential of current small molecule drug targeted therapy.

[0014] ②Protein degradation targeted chimera (PROTAC) molecular technology

[0015] PROTAC is a bifunctional molecule that can bind to E3 ubiquitin ligase and target protein (POI) at the same time. By "hijacking" the ubiquitin-proteasome system (UPS), lysine exposed to the target protein is ubiquitinated by the E3 ubiquitinase complex, and then the proteasome degrades the POI. Unlike traditional methods, PROTAC aims to eliminate target proteins at the post-translational level rather than inhibiting their synthesis. This targeted protein degradation technology has great potential to target "undruggable" proteins, which account for about 85% of all human proteins. Small molecule PROTAC has achieved great success in the study of degrading a series of proteins, and more and more PROTAC applications are gradually entering the clinic.

[0016] However, due to the high cost of PROTAC chemical synthesis and its high molecular weight, its absorption and drugability are poor. In addition, if PROTAC cannot bind to the target protein after entering the body, its off-target toxicity is also worthy of attention. Therefore, PROTAC technology still has room for optimization and improvement.

[0017] ③Molecular glue technology

[0018] The chemical structure of molecular glue is much simpler than that of PROTAC, and the degradation principle is similar to that of PROTAC, except that molecular glue plays an inducing role. It can induce the enzymes in the multi-level enzyme chain of the ubiquitin-proteasome pathway to connect with the target protein, forming a protein-small molecule-protein ternary complex, so that the target protein is marked with ubiquitination and ultimately degraded.

[0019] Molecular glues usually have a smaller molecular weight, less spatial interference, and better drugability, but their design is very difficult, and most of the molecular glues reported so far were discovered accidentally during research.

[0020] ④ Biomacromolecule targeted degradation system——TrimAway technology

[0021] A new protein degradation strategy, TrimAway, was reported in the journal Cell. The principle is to introduce antibodies to the target protein into the cell by microinjection or electroporation (the variable region and constant region of the antibody serve as the targeting module and E3 enzyme recruitment module of the system, respectively) to achieve highly specific recognition of the antigen (target protein), and further use the E3 ligase TRIM21 to recognize the Fc region of the antibody, and mediate the antibody-dependent intracellular neutralization effect (antibody-dependent intracellular neutralization, ADIN), so that the antigen-antibody complex is ubiquitinated and then degraded via the ubiquitin-proteasome pathway, thereby ultimately achieving specific recognition and degradation of the target protein. This technology achieves specific recognition of the target protein through antigen-antibody specific hybridization reactions, avoiding the unavoidable off-target effects of CRISPR technology, PROTACs technology, RNAi technology, etc. At the same time, because the TrimAway technology also has the characteristics of high efficiency and scalability, it can achieve complete removal of the target protein within a dozen minutes.

[0022] However, the process of introducing antibodies using the TrimAway method requires the use of microinjection, electroporation and other technologies, which not only requires high instrumentation requirements, but also inevitably affects the physiological state of cells, which limits the widespread application of this technology in the field of basic research. The limitations of the antibody introduction method and the fact that some endogenous TRIM21 in cells is insufficient to support the degradation process also determine that this technology cannot be applied at the clinical level. Summary of the invention

[0023] The purpose of the present invention is to provide an ORF, a plasmid and an mRNA for targeted degradation of intracellular proteins, and a method for using and application thereof, so as to solve the problems that the existing protein interference technology at the DNA and RNA levels has a small scope of application; small molecule drugs have a large dosage, are not universal and are easy to off-target; PROTAC chemical synthesis costs are high, and the absorbability and drugability are poor, and there is off-target toxicity; protein targeted degradation technology based on the ubiquitination pathway still has the problems of complex introduction of targeting modules and unfriendly modes of action.

[0024] To achieve the above-mentioned purpose, the present invention provides an open reading frame, which consists of a targeting module, a connecting module and a degradation module, wherein the targeting module and the degradation module are connected through the connecting module; the targeting module is selected according to the target protein and is any polypeptide or protein that specifically binds to the target protein; the connecting module is a GSSS flexible peptide.

[0025] Preferably, the targeting module is one of a single-chain antibody and a single-domain antibody.

[0026] Preferably, the degradation module is one of the full length of TRIM21 protein, RING-B-Box-Coil, RIGN-Coil-PRYSPRY, and RIGN.

[0027] An mRNA comprising the above open reading frame, wherein the structure of the mRNA 5′-3′ is: 5′cap-5′UTR-open reading frame-3′UTR-PolyA, the sequence of 3′UTR is shown in SEQ ID NO.2, and the sequence of 5′UTR is shown in SEQ ID NO.3.

[0028] A method for using the above mRNA to target and degrade intracellular proteins, comprising the following steps:

[0029] S1, incubating the synthesized mRNA with lipid nanoparticles in an acidic buffer to form drug-loaded nanoparticles encapsulating mRNA, which enter cells through endocytosis;

[0030] S2. After the drug-loaded nanoparticles encapsulating mRNA enter the cells, they escape through the endosomes, complete translation and folding in the cytoplasm, and self-assemble into a degradation system. The targeting module in the degradation system specifically recognizes and binds to the target protein, triggering the E3 ligase function of TRIM21, achieving ubiquitination marking of the target protein-degradation system complex, and then achieving degradation of the target protein via the ubiquitin-proteasome pathway.

[0031] Preferably, in step S1, the mRNA is dissolved in a sodium citrate buffer at pH 4-6 to form an mRNA solution with a concentration of 170 ng / μL; the lipid nanoparticles are LNP1273, wherein the HUO (SM-102) content is 50%, the DSPC content is 10%, the Chol content is 38.4%, and the dmg-PEG2000 content is 1.5%, and the LNP1273 is dissolved in ethanol to obtain a lipid nanoparticle suspension, the volume ratio of the mRNA solution to the lipid nanoparticle suspension is 3:1, and the acidic buffer is a sodium citrate buffer at pH 4-6.

[0032] An application of the mRNA targeted degradation method for intracellular proteins as described above in protein degradation for non-medical purposes.

[0033] A plasmid comprising the above open reading frame.

[0034] A use of the mRNA or plasmid as described above in protein degradation for non-medical purposes.

[0035] TRIM21 protein contains four domains: RING, B-box, Coil and PRYSPRY. Under normal physiological conditions, RING has ubiquitination activity, B-box maintains the stability of the three-dimensional structure of the protein, Coil promotes homodimerization of TRIM21 molecules, and PRYSPRY is a three-dimensional folded structure. Through optimization experiments, the present invention found that only the RING, B-box and Coil domains of TRIM21 protein can achieve the function.

[0036] Lipid nanoparticles (LNP) are the most advanced mRNA delivery vectors in clinical practice. LNP usually includes four components: ionizable lipids, cholesterol, auxiliary phospholipids, and PEGylated lipids. These components form nanoparticles with mRNA in an acidic buffer, which together encapsulate and protect fragile mRNA and enter cells through endocytosis.

[0037] Therefore, the ORF, plasmid and mRNA for targeted degradation of intracellular proteins provided by the present invention and their use methods and applications have the following specific technical effects:

[0038] (1) The method provided by the present invention can effectively and continuously degrade the target protein, realize the specific recognition function of the target protein through the antigen-antibody specific hybridization reaction, avoid the unavoidable off-target effects of CRISPR technology, PROTACs technology, RNAi technology, etc., and has universal applicability;

[0039] (2) The method provided by the present invention is simple and easy to operate in introducing the targeting module, and does not require pre-modification of the target protein;

[0040] (3) The method provided by the present invention has the advantages of high efficiency and scalability, and can achieve complete elimination of the target protein within a dozen minutes;

[0041] (4) The method provided by the present invention utilizes the human body's own translation mechanism to produce proteins, which is highly safe. As a nucleic acid drug, mRNA drugs can be safely and efficiently delivered to specific target cells and protect them from degradation. They do not need to enter the cell nucleus, which can effectively avoid the safety risks of genome integration and cell transformation.

[0042] (5) The production of mRNA drugs is safe and reliable. It is produced through enzymatic in vitro transcription (IVT) reactions and does not rely on the cell expansion process, thus avoiding the complex production problems associated with cell culture.

[0043] The technical solution of the present invention is further described in detail below through the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS

[0044] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments of the present invention will be briefly introduced below. Obviously, the accompanying drawings in the following description are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative labor.

[0045] Figure 1 It is a schematic diagram of the composition and expression strategy of the mRNA degradation system provided by the present invention;

[0046] Figure 2 It is a schematic diagram of the degradation principle of the mRNA and plasmid degradation system provided by the present invention;

[0047] Figure 3 Schematic diagram of the structure of the ORF part of the five degradation systems constructed in Example 4 of the present invention;

[0048] Figure 4 It is T21-DP in the embodiment of the present invention. K (plasmid), DP K -F T21(mRNA), T21-DP K (mRNA) Western blot results of H358 cells transfected for 48 h, Con is the empty cell without transfection;

[0049] Figure 5 It is T21-DP in the third embodiment of the present invention. K (mRNA) Western blot results at 0, 12, 24, 36, 48, 60, and 72 h of transfection;

[0050] Figure 6The results of western blot detection of H358 cells transfected with the five mRNA degradation systems in Example 4 of the present invention for 48 hours;

[0051] Figure 7 It is a schematic diagram of the structure of the ORF part of the recombinant plasmid in Example 5 of the present invention;

[0052] Figure 8 This is the result of laser confocal microscopy observation of 293T cells transfected with eGFP by the plasmid degradation system in Example 5 of the present invention for 24h and 48h;

[0053] Fig. 9 The results of flow cytometric analysis of the eGFP fluorescence intensity of 293T cells transfected with the plasmid degradation system in Example 5 of the present invention at 24h and 48h;

[0054] Fig.10 The results of laser confocal microscopy observation of eGFP in 293T cells transfected with the plasmid degradation system treated with and without MG132 in Example 5 of the present invention for 24h and 48h;

[0055] Fig.11 The fluorescence intensity of eGFP was detected by a microplate reader at 24h and 48h after 293T cells were transfected with the plasmid degradation system treated with MG132 and without MG132 in Example 5 of the present invention. DETAILED DESCRIPTION

[0056] The present invention provides an open reading frame (ORF), which is composed of a targeting module, a connecting module and a degradation module. The targeting module and the degradation module are connected through the connecting module. The structure is as follows Figure 1 As shown. The targeting module is selected according to the target protein, which is any polypeptide or protein that specifically binds to the target protein, and is one of a single-chain antibody and a single-domain antibody. The connecting module is a GSSS flexible peptide. The degradation module is a part of the TRIM21 protein, including the RING, B-box and Coil domains of the TRIM21 protein.

[0057] The present invention provides an mRNA and a plasmid comprising the above ORF, wherein the targeting module, the connection module and the degradation module are expressed as a fusion protein. The expression strategy is as follows: Figure 1 As shown. The target protein can be degraded by using mRNA and plasmid including the above ORF. The degradation principle is as follows Figure 2 shown.

[0058] The technical solution of the present invention is further described below through the accompanying drawings and embodiments.

[0059] In order to make the purpose, technical scheme and advantages of the present application clearer, more thorough and more complete, the technical scheme of the present invention is clearly and completely described below through the accompanying drawings and examples. The following detailed descriptions are all descriptions of the embodiments, and are intended to provide further detailed descriptions of the present invention. Unless otherwise specified, all technical terms used in the present invention have the same meaning as those generally understood by those skilled in the art to which the present application belongs.

[0060] The instruments, equipment, reagents and materials used in the examples were all obtained through commercial channels.

[0061] Embodiment 1

[0062] The mRNA containing the above open reading frame (ORF) is used to degrade KRAS protein, and the specific steps are as follows:

[0063] S1.1、DP K (Designed ankyrin repeat proteins), that is, the nucleic acid sequence of the designed ankyrin repeat fold protein is used as the targeting module, and the full length of TRIM21 protein is used as the degradation module, DP K The amino acid sequence is shown in SEQ ID NO.1. The nucleotide sequence of the targeting module, the sequence of the GSSS flexible peptide, the full-length sequence of the TRIM21 protein (including the four domains of RING, B-box, Coil and PRYSPRY), the 3′UTR, the 5′UTR, and the sequence of PolyA were sent to the company for Figure 1 The sequence shown is sequentially connected to the PUC57 plasmid to prepare a recombinant plasmid, and the PUC57 plasmid has a unique BSPQI restriction site. The sequence of the 3'UTR is shown in SEQ ID NO.2, and the sequence of the 5'UTR is shown in SEQ ID NO.3.

[0064] SEQ ID NO.1:

[0065] MDLGKKLLEAARAGQDDEVRILMANGADVNASDRWGWTPLHLAAWWGHLEIVEVLLKRGADVSAADLHGQSPLHLAAMVGHLEIVEVLLKYGADVNAKDTMGATPLHLAARSGHLEIVEELLKNGADMNAQDKFGKTTFDISTDNGNEDLAEILQKL

[0066] SEQ ID NO.2:

[0067] CTGGTACTGCATGCACGCAATGCTAGCTGCCCCTTTCCCGTCCTGGGTACCCCGAGTCTCCCCGACCTCGGGTCCCAGGTATGCTCCCACCTCCACCTGCCCCACTCACCACCTCTGCTAGTTCCAGACACCTCCCAAGCACG CAGCAATGCAGCTCAAAACGCTTAGCCTAGCCACACCCCCACGGGAAACAGCAGTGATTAACCTTTAGCAATAAACGAAAGTTTAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCCACACCCTGGAGCTAGC

[0068] SEQ ID NO.3:TAGTATTCTTCTGGTCCCCACAGACTCAGAGAGAACCCGCCACC S1.2. The obtained recombinant plasmid was transformed into E. coli DH5α, cultured overnight (12-16h) at 37°C and 200rpm, and the plasmid was extracted using a kit to obtain the PUC57 recombinant plasmid. The obtained PUC57 recombinant plasmid was digested with BSPQI enzyme according to the instructions attached to the enzyme to obtain a linear plasmid.

[0069] S1.3, the obtained linear plasmid was transcribed in vitro, the transcription system is shown in Table 1, incubated at 37°C for 2h, 2μL DNase I was added, mixed evenly, and incubated at 37°C for 30min. The AG column purification kit was used for purification to obtain the mRNA with the 5′ cap added, named T21-DP K (mRNA), dilute the mRNA to 170 ng / μL with pH 5 citrate buffer to obtain an mRNA solution.

[0070] Table 1

[0071] Nuclease-freeWater Make up to 20 μL 100mM ATP Solution 1.6μL 100mMGTPSolution 1.6μL 100mM CTP solution 1.6μL <![CDATA[100mMN 1 -Me-PseudoUTPsolution]]> 1.6μL 100mMCapAnalog 1.6μL Linear plasmid 1ug 5×ReactionBuffer 4μL EnzymeMix 1.5μL

[0072] S1.4. Take 29.4 μL of the mRNA solution obtained in step S1.3, add 9.8 μL of LNP1273 lipid nanoparticles, and incubate at room temperature for 10 min to obtain drug-loaded nanoparticles encapsulating mRNA.

[0073] LNP1273 lipid nanoparticles are composed of 50% HUO (SM-102), 10% DSPC, 38.4% Chol, and 1.5% dmg-PEG2000, which are dissolved in 75% ethanol to obtain a lipid nanoparticle suspension (LNP).

[0074] S1.5, T21-DP via LNP K (mRNA) was transfected into H358 cells (schematic diagram of the structure is shown in Figure 3 As shown in 2), collect cells at 48h. Add 200μL cell lysis buffer (RIPA strong lysis buffer: PMSF volume ratio of 100:1 mixture), lyse on ice for 30min, centrifuge at 4℃, 14000xg for 10min, take 182μL supernatant, take 2μL for BCA protein concentration determination, add 5×buffer 45μL to the remaining 180μL, boil for 5min, cool, and calculate the protein concentration of each tube according to the standard curve. The sample volume is 20ng for loading (the volume is filled with 1×buffer) for western blot detection, and the results are as follows Figure 4 shown.

[0075] Embodiment 2

[0076] The recombinant plasmid containing the above ORF is used to degrade KRAS protein. The specific steps are as follows:

[0077] S2.1、DP K The nucleic acid sequence of DP-1 was used as the targeting module, and the full length of TRIM21 protein was used as the degradation module. K The amino acid sequence of is shown in SEQ ID NO.1. The nucleotide sequence of the targeting module, the sequence of the GSSS flexible peptide, and the full-length sequence of the TRIM21 protein were sent to the company for Figure 1 The sequence shown was connected to the pcDNA (3.1) plasmid to prepare the recombinant plasmid T21-DP K .

[0078] S2.2, after the obtained recombinant plasmid was transformed into E. coli DH5α, it was cultured overnight at 37°C and 200 rpm (12-16 hours), and the plasmid was extracted using a kit to obtain the pcDNA (3.1) recombinant plasmid. The obtained pcDNA (3.1) recombinant plasmid was transfected with 2.5 μg T21-DP using lipo3000 K (plasmid) to H358 cells, and collect cells at 48h. Add 200μL cell lysis buffer (RIPA strong lysis buffer: PMSF volume ratio of 100:1 mixture), lyse on ice for 30min, centrifuge at 4℃, 14000xg for 10min, take 182μL supernatant, take 2μL for BCA protein concentration determination, add 5×buffer 45μL to the remaining 180μL, boil for 5min, cool, and calculate the protein concentration of each tube according to the standard curve. The sample volume is 20ng for loading (the volume is filled with 1×buffer) for western blot detection, and the results are as follows Figure 4 shown.

[0079] Comparative Example 1

[0080] The TrimAway technology was used to prepare mRNA comprising the targeting module and the degradation module of Example 1 to degrade KRAS protein. The specific steps were exactly the same as those of Example 1, except that the PUC57 recombinant plasmid in step S1.1 was as follows:

[0081] The nucleic acid sequence of was used as the targeting module, and the full length of TRIM21 protein was used as the degradation module. K The amino acid sequence of the targeting module, the full-length sequence of TRIM21 protein, the FC region sequence and the P2A sequence were sent to the company for Figure 3 1) were sequentially connected to the PUC57 plasmid to prepare a recombinant plasmid, and the steps were exactly the same as in Example 1 to prepare mRNA, named DP K - FT21 (mRNA).

[0082] The results are as follows Figure 4 As shown by Figure 4 It can be seen that the mRNA degradation system constructed in Example 1 and the plasmid degradation system constructed in Example 2 were successfully expressed in H358 cells. After the plasmid and mRNA forms were introduced, they both played the role of degrading KRAS protein in the cells. Compared with the TrimAway technology (Comparative Example 1), the fusion protein form can achieve the same effect of degrading KRAS protein.

[0083] Embodiment 3

[0084] The optimal degradation time of KRAS protein by the mRNA degradation system prepared in Example 1 was investigated, and the specific steps were as follows:

[0085] The ORF structure obtained by the method of Example 1 is T21-DP K (See Figure 3 2)) mRNA, and the method of Example 1 was used for encapsulation, and 5 μg T21-DP was transfected into H358 cells by LNP at the same time. K mRNA, cells were collected at 0, 12, 24, 36, 48, 60, and 72 h after transfection, and protein expression was detected by western blot after lysis. The results are shown in Figure 5 As shown, the degradation system can be sustainably expressed in the cells, and obvious degradation effect appears 24 hours after the degradation system is transferred into the cells, and can be maintained up to 72 hours.

[0086] Embodiment 4

[0087] Too long mRNA will affect the stability of mRNA, so the linker sequence of TRIM21 protein is optimized to improve the stability of mRNA. The specific steps are as follows:

[0088] The method of embodiment 1 is used to construct the following Figure 3 The degradation systems of the five degradation modules shown in 1)-5) were respectively encapsulated by LNP and transfected into H358 cells. After 48 hours, the cells were collected and lysed, and the protein expression levels were detected by western blot. The results are shown in FIG. Figure 6 As shown, through screening, degradation systems 1), 2), and 3) showed obvious degradation effects after being transferred into cells, and could degrade 60-70% of KRAS protein. The degradation effects of degradation systems 4) and 5) were poor, reaching 30-40%, indicating that the deletion of B-BOX and Coil sequences had an adverse effect on the function of the degradation system.

[0089] Embodiment 5

[0090] The eGFP protein was degraded using a plasmid containing the above open reading frame (ORF), and the specific steps are as follows:

[0091] S5.1. DP e (eGFP designed ankyrin repeat fold protein) as the targeting module. The nucleotide sequence of the targeting module, the full-length sequence of TRIM21 protein, the FC region sequence and the P2A sequence were sent to the company for Figure 7 The sequence shown was sequentially connected to the pcDNA3.1 plasmid to prepare a recombinant plasmid, named 1)DP e -F T21, 2) T21-DP e .

[0092] S5.2. Transform the received recombinant plasmid into E. coli DH5α and culture overnight at 37°C and 200 rpm (12-16 h). Use a kit to extract the plasmid and co-transfect 2.5 μg eGFP and 2.5 eGFP Predator 1) and 2) plasmid expression vectors into 293T cells using lipo3000.

[0093] Laser confocal microscopy was used to observe the expression of eGFP. Figure 8 As shown, the fluorescence intensity of eGFP decreased 24h and 48h after transfection, that is, both eGFPPredator 1) and 2) had a degradation effect on eGFP and the degradation could be continuous.

[0094] S5.3. Analyze the fluorescence intensity of eGFP in cells using flow cytometry. The results are as follows: Fig. 9As shown in the figure, the peak value of eGFP shifted to the left at 24h after transfection, that is, the fluorescence intensity of eGFP decreased. Therefore, eGFP Predator has a degradation effect on eGFP, and DP e -F T21 has better degradation effect.

[0095] S5.4. Investigate whether eGFP degradation is through the ubiquitin proteasome pathway

[0096] In the presence / absence of MG132 (proteasome inhibitor, final concentration of 5 μM), 2.5 μg of eGFP and 2.5 eGFP Predator 1) and 2) plasmid expression vectors were co-transfected into 293T cells by lipo3000. The degradation effect of eGFP was observed using an inverted fluorescence microscope. Fig.10 As shown, the fluorescence intensity of eGFP was detected by an enzyme-labeled instrument. Fig.11 As shown by Fig.10 and 11 It can be seen that the proteasome inhibitor MG132 has no effect on the expression of eGFP; DP e -F T21 and T21-DP e After adding the proteasome inhibitor MG132, DP e -F T21 and T21-DP e The degradation of eGFP is inhibited, so the degradation effect is degraded by the ubiquitin proteasome degradation system.

[0097] Therefore, the method provided by the present invention can effectively and continuously degrade the target protein, has high efficiency and scalability, and can achieve complete elimination of the target protein within a dozen minutes; the specific recognition function of the target protein is realized through the antigen-antibody specific hybridization reaction, avoiding the unavoidable off-target effects of CRISPR technology, PROTACs technology, RNAi technology, etc., and has universal applicability; the introduction of the targeting module is simple and easy to operate, and no pre-modification of the target protein is required; mRNA drugs can be safely and efficiently delivered to specific target cells and protect them from degradation, and do not need to enter the cell nucleus, which can effectively avoid the safety risks of genome integration and cell transformation; the production is safe and reliable, and is produced through enzymatic in vitro transcription (IVT) reactions, without relying on the cell amplification process, avoiding complex production problems related to cell culture.

[0098] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solution of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solution to deviate from the spirit and scope of the technical solution of the present invention.

Claims

1. An open reading frame characterized by: It consists of a targeting module, a connecting module and a degradation module, wherein the targeting module and the degradation module are connected via the connecting module; the targeting module is selected according to the target protein and is any polypeptide or protein that specifically binds to the target protein; the connecting module is a GSSS flexible peptide.

2. An open reading frame according to claim 1, characterized in that: The targeting module is a single-chain antibody or a single-domain antibody.

3. An open reading frame according to claim 1, characterized in that: The degradation module is one of the full length of TRIM21 protein, RING-B-Box-Coil, RIGN-Coil-PRYSPRY, and RIGN.

4. An mRNA comprising the open reading frame according to any one of claims 1 to 3, characterized in that: The structure of mRNA 5′-3′ is: 5′cap-5′UTR-open reading frame-3′UTR-PolyA, the sequence of 3′UTR is shown in SEQ ID NO.2, and the sequence of 5′UTR is shown in SEQ ID NO.

3.

5. A method for targeting and degrading intracellular proteins using the mRNA according to claim 4, characterized in that: Here are the steps: S1, incubating the synthesized mRNA with lipid nanoparticles in an acidic buffer to form drug-loaded nanoparticles encapsulating mRNA, which enter cells through endocytosis; S2. After the drug-loaded nanoparticles encapsulating mRNA enter the cells, they escape through the endosomes, complete translation and folding in the cytoplasm, and self-assemble into a degradation system. The targeting module in the degradation system specifically recognizes and binds to the target protein, triggering the E3 ligase function of TRIM21, achieving ubiquitination marking of the target protein-degradation system complex, and then achieving degradation of the target protein via the ubiquitin-proteasome pathway.

6. A method for targeting intracellular protein degradation using mRNA according to claim 5, characterized in that: In step S1, mRNA is dissolved in a sodium citrate buffer at pH 4-6 to form an mRNA solution with a concentration of 170 ng / μL, the lipid nanoparticles are LNP1273, wherein the HUO (SM-102) content is 50%, the DSPC content is 10%, the Chol content is 38.4%, and the dmg-PEG2000 content is 1.5%, and LNP1273 is dissolved in ethanol to obtain a lipid nanoparticle suspension, the volume ratio of the mRNA solution to the lipid nanoparticle suspension is 3:1, and the acidic buffer is a sodium citrate buffer at pH 4-6.

7. Use of the method for mRNA targeted degradation of intracellular proteins as claimed in claim 5 or 6 in protein degradation for non-medical purposes.

8. A plasmid comprising the open reading frame according to any one of claims 1 to 3.

9. Use of the mRNA according to claim 4 or the plasmid according to claim 8 in protein degradation for non-medical purposes.

Citation Information

Patent Citations

  • Intracellular immunity

    CN103180340A

  • Improved ice-based lipid nanoparticle formulation for delivery of mRNA

    CN110114058A

  • Fusion protein and application thereof in targeted degradation of intracellular protein

    CN113292658A

  • Preparation method and application of TRIM21 full-length protein

    CN113651879A

  • Compositions, methods and uses of messenger RNA

    CN115279418A

Cited By

  • Nucleic acid molecule targeting SARS-CoV-2 virus Spike protein, recombinant expression vector containing nucleic acid molecule and application

    CN122146697A